RxDoctor Payments Data

Hannah Cheek

Family · Valdosta, GANPI 1316573934

Payments from drug & device makers

$1,134in general payments, 2019–2025

Across 61 payments — averaging $18.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$382
  • Amgen$184
  • Bayer$132
  • Myovant Sciences Inc.$121
  • Lilly USA, LLC$68
  • Otsuka America Pharmaceutical, Inc.$56
  • plus $192 from 7 others

What the payments were for

  • Food & beverage$1,134100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,134 in reported general payments places this provider in the 70th percentile of 6,258 family providers in Georgia.

See all family providers in Georgia

Medicare billing

Part B allowed, 2024
$21,164
Medicare patients
53
Services billed
243

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide60$90,381
Breztri AerosphereBudesonide/Glycopyr/Formoterol40$40,005
JardianceEmpagliflozin38$39,288
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$28,194
LinzessLinaclotide28$20,470
EliquisApixaban32$20,133
TrulicityDulaglutide14$15,692
OzempicSemaglutide11$10,370
Tresiba Flextouch U-200Insulin Degludec13$9,422
MyrbetriqMirabegron21$9,217
JanuviaSitagliptin Phosphate13$7,103
Albuterol Sulfate HfaAlbuterol Sulfate42$1,202
Fluticasone Propionate56$1,146
Gabapentin87$1,049
Ranolazine ErRanolazine17$1,043

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$68$106,07374 claims
AstraZenecaBreztri Aerosphere$31$40,00540 claims
Boehringer IngelheimJardiance$23$39,28838 claims
GSKTrelegy Ellipta$34$28,19424 claims
AbbVieLinzess$382$20,47028 claims
Novo NordiskOzempic$23$10,37011 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 6,258 family providers in Georgia.

Other family in Valdosta

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →